<DOC>
	<DOCNO>NCT00252785</DOCNO>
	<brief_summary>The primary objective study confirm efficacy ( superiority ) Symbicort® Turbuhaler® 160/4.5 µg twice daily 8 week comparison Pulmicort® Turbuhaler® 200 µg twice daily + Theolong® tablet 200 mg twice daily .</brief_summary>
	<brief_title>Efficacy &amp; Safety Symbicort® TURBUHALER® 160/4.5 µg Twice Daily &amp; Pulmicort® TURBUHALER® 200 µg Twice Daily + Theolong® Tablet 200 mg Twice Daily Japanese Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide , Formoterol Fumarate Drug Combination</mesh_term>
	<criteria>Diagnosis asthma document history least 6 month duration prior Visit 1 Prescribed daily use IGCS &gt; =12 week prior Visit 1 . The dose IGCS must 400 800 µg/day Pulmicort® Turbuhaler® correspond dose IGCS . The prescribed dose IGCS constant least 4 week prior Visit 1 Prescribed daily use sustain release theophylline least 8 week prior Visit 1 , confirm steadystate blood theophylline concentration within effective range ( 515 µg/mL ) 8 week prior Visit 1 . The prescribed dose theophylline constant ( 400 mg/day ) least 4 week prior Visit 1 Any significant disease disorder may jeopardize safety patient Respiratory infection , judge investigator ( ) infection affect asthma , within 4 week prior Visit 1 Treatment oral , parenteral rectal GCS within 4 week prior Visit 1 Additional inclusion exclusion criterion evaluate Investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
</DOC>